GULLIVERS FLEA & TICK COLLAR FOR DOGS
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
27-04-2024
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
DIMPYLATE
Available from:
Chanelle Pharmaceuticals Manufacturing Limited
ATC code:
QP53AF03
INN (International Name):
DIMPYLATE
Dosage:
3.9 Grams
Pharmaceutical form:
Collar
Prescription type:
CAM-Companion Animal Medicine
Therapeutic group:
Canine
Therapeutic area:
Dimpylate
Therapeutic indications:
Ectoparasiticide
Authorization status:
Authorised
Authorization date:
1989-10-01
Summary of Product characteristics
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Gullivers Flea & Tick Collar for dogs.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Per collar:
ACTIVE SUBSTANCE:
Dimpylate (as stabilized diazinon at 92% diazinon) 3.9 g
EXCIPIENTS:
Carbon black (E153)
0.004 g
For a full list of excipeints, see section 6.1
3 PHARMACEUTICAL FORM
Collar.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of infestation of dogs with fleas (Ctenocephalides felis) and ticks (Ixodes ricinus).
4.3 CONTRAINDICATIONS
Do not use in case of known hypersensitivity to the active ingredient.
Do not use on sick and recovering dogs.
Do not use in dogs with known liver disorder.
Do not use in pregnant bitches.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None known.
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 25/02/2011_
_CRN 7005997_
_page number: 1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
None.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE PRODUCT TO ANIMALS
Due to the potential risk of hypersensitivity developing in humans to dimpylate, unnecessary handling of this product
should be avoided.
4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
An intoxication typical for organophosphorus compounds occurs rarely.
4.7 USE DURING PREGNANCY, LACTATION OR LAY
Use during pregnancy is not recommended.
4.8 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION
Do not combine with other organophosphorous compounds or medicines which are not compatible with
organophosphorous compounds.
4.9 AMOUNTS TO BE ADMINISTERED AND ADMINISTRATION ROUTE
Dosage : 1 collar
Administration: put the col
Read the complete document
